Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older

Chris J L M Meijer, Johannes Berkhof, Philip E. Castle, Albertus T. Hesselink, Eduardo L. Franco, Guglielmo Ronco, Marc Arbyn, F. Xavier Bosch, Jack Cuzick, Joakim Dillner, Danielle A M Heideman, Peter J F Snijders

Research output: Contribution to journalArticle

374 Citations (Scopus)

Abstract

Given the strong etiologic link between high-risk HPV infection and cervical cancer high-risk HPV testing is now being considered as an alternative for cytology-based cervical cancer screening. Many test systems have been developed that can detect the broad spectrum of hrHPV types in one assay. However, for screening purposes the detection of high-risk HPV is not inherently useful unless it is informative for the presence of high-grade cervical intraepithelial neoplasia (CIN 2/3) or cancer. Candidate high-risk HPV tests to be used for screening should reach an optimal balance between clinical sensitivity and specificity for detection of high-grade CIN and cervical cancer to minimize redundant or excessive follow-up procedures for high-risk HPV positive women without cervical lesions. Data from various large screening studies have shown that high-risk HPV testing by hybrid capture 2 and GP5+/6+-PCR yields considerably better results in the detection of CIN 2/3 than cytology. The data from these studies can be used to guide the translation of high-risk HPV testing into clinical practice by setting standards of test performance and characteristics. On the basis of these data we have developed guidelines for high-risk HPV test requirements for primary cervical screening and validation guidelines for candidate HPV assays.

Original languageEnglish (US)
Pages (from-to)516-520
Number of pages5
JournalInternational Journal of Cancer
Volume124
Issue number3
DOIs
StatePublished - Feb 1 2009
Externally publishedYes

Fingerprint

Human Papillomavirus DNA Tests
Early Detection of Cancer
Uterine Cervical Neoplasms
Guidelines
Cell Biology
Cervical Intraepithelial Neoplasia

Keywords

  • Cervical screening
  • HPV test guidelines
  • HPV test requirements
  • HPV test statistics
  • HPV-DNA testing

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. / Meijer, Chris J L M; Berkhof, Johannes; Castle, Philip E.; Hesselink, Albertus T.; Franco, Eduardo L.; Ronco, Guglielmo; Arbyn, Marc; Bosch, F. Xavier; Cuzick, Jack; Dillner, Joakim; Heideman, Danielle A M; Snijders, Peter J F.

In: International Journal of Cancer, Vol. 124, No. 3, 01.02.2009, p. 516-520.

Research output: Contribution to journalArticle

Meijer, CJLM, Berkhof, J, Castle, PE, Hesselink, AT, Franco, EL, Ronco, G, Arbyn, M, Bosch, FX, Cuzick, J, Dillner, J, Heideman, DAM & Snijders, PJF 2009, 'Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older', International Journal of Cancer, vol. 124, no. 3, pp. 516-520. https://doi.org/10.1002/ijc.24010
Meijer, Chris J L M ; Berkhof, Johannes ; Castle, Philip E. ; Hesselink, Albertus T. ; Franco, Eduardo L. ; Ronco, Guglielmo ; Arbyn, Marc ; Bosch, F. Xavier ; Cuzick, Jack ; Dillner, Joakim ; Heideman, Danielle A M ; Snijders, Peter J F. / Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. In: International Journal of Cancer. 2009 ; Vol. 124, No. 3. pp. 516-520.
@article{da34bf6166af4a55a8f79c0043861b44,
title = "Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older",
abstract = "Given the strong etiologic link between high-risk HPV infection and cervical cancer high-risk HPV testing is now being considered as an alternative for cytology-based cervical cancer screening. Many test systems have been developed that can detect the broad spectrum of hrHPV types in one assay. However, for screening purposes the detection of high-risk HPV is not inherently useful unless it is informative for the presence of high-grade cervical intraepithelial neoplasia (CIN 2/3) or cancer. Candidate high-risk HPV tests to be used for screening should reach an optimal balance between clinical sensitivity and specificity for detection of high-grade CIN and cervical cancer to minimize redundant or excessive follow-up procedures for high-risk HPV positive women without cervical lesions. Data from various large screening studies have shown that high-risk HPV testing by hybrid capture 2 and GP5+/6+-PCR yields considerably better results in the detection of CIN 2/3 than cytology. The data from these studies can be used to guide the translation of high-risk HPV testing into clinical practice by setting standards of test performance and characteristics. On the basis of these data we have developed guidelines for high-risk HPV test requirements for primary cervical screening and validation guidelines for candidate HPV assays.",
keywords = "Cervical screening, HPV test guidelines, HPV test requirements, HPV test statistics, HPV-DNA testing",
author = "Meijer, {Chris J L M} and Johannes Berkhof and Castle, {Philip E.} and Hesselink, {Albertus T.} and Franco, {Eduardo L.} and Guglielmo Ronco and Marc Arbyn and Bosch, {F. Xavier} and Jack Cuzick and Joakim Dillner and Heideman, {Danielle A M} and Snijders, {Peter J F}",
year = "2009",
month = "2",
day = "1",
doi = "10.1002/ijc.24010",
language = "English (US)",
volume = "124",
pages = "516--520",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older

AU - Meijer, Chris J L M

AU - Berkhof, Johannes

AU - Castle, Philip E.

AU - Hesselink, Albertus T.

AU - Franco, Eduardo L.

AU - Ronco, Guglielmo

AU - Arbyn, Marc

AU - Bosch, F. Xavier

AU - Cuzick, Jack

AU - Dillner, Joakim

AU - Heideman, Danielle A M

AU - Snijders, Peter J F

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Given the strong etiologic link between high-risk HPV infection and cervical cancer high-risk HPV testing is now being considered as an alternative for cytology-based cervical cancer screening. Many test systems have been developed that can detect the broad spectrum of hrHPV types in one assay. However, for screening purposes the detection of high-risk HPV is not inherently useful unless it is informative for the presence of high-grade cervical intraepithelial neoplasia (CIN 2/3) or cancer. Candidate high-risk HPV tests to be used for screening should reach an optimal balance between clinical sensitivity and specificity for detection of high-grade CIN and cervical cancer to minimize redundant or excessive follow-up procedures for high-risk HPV positive women without cervical lesions. Data from various large screening studies have shown that high-risk HPV testing by hybrid capture 2 and GP5+/6+-PCR yields considerably better results in the detection of CIN 2/3 than cytology. The data from these studies can be used to guide the translation of high-risk HPV testing into clinical practice by setting standards of test performance and characteristics. On the basis of these data we have developed guidelines for high-risk HPV test requirements for primary cervical screening and validation guidelines for candidate HPV assays.

AB - Given the strong etiologic link between high-risk HPV infection and cervical cancer high-risk HPV testing is now being considered as an alternative for cytology-based cervical cancer screening. Many test systems have been developed that can detect the broad spectrum of hrHPV types in one assay. However, for screening purposes the detection of high-risk HPV is not inherently useful unless it is informative for the presence of high-grade cervical intraepithelial neoplasia (CIN 2/3) or cancer. Candidate high-risk HPV tests to be used for screening should reach an optimal balance between clinical sensitivity and specificity for detection of high-grade CIN and cervical cancer to minimize redundant or excessive follow-up procedures for high-risk HPV positive women without cervical lesions. Data from various large screening studies have shown that high-risk HPV testing by hybrid capture 2 and GP5+/6+-PCR yields considerably better results in the detection of CIN 2/3 than cytology. The data from these studies can be used to guide the translation of high-risk HPV testing into clinical practice by setting standards of test performance and characteristics. On the basis of these data we have developed guidelines for high-risk HPV test requirements for primary cervical screening and validation guidelines for candidate HPV assays.

KW - Cervical screening

KW - HPV test guidelines

KW - HPV test requirements

KW - HPV test statistics

KW - HPV-DNA testing

UR - http://www.scopus.com/inward/record.url?scp=58149292268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149292268&partnerID=8YFLogxK

U2 - 10.1002/ijc.24010

DO - 10.1002/ijc.24010

M3 - Article

VL - 124

SP - 516

EP - 520

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -